Apogee Therapeutics, Inc.

NASDAQ:APGE

Biotechnology

Healthcare
$135.07 +1.18%

+$1.05 today

Market cap
$8.36B
Beta
0.62
P/E (TTM)
-22.7
EPS (TTM)
-$3.94
52W Low $34.34High $95.32

Volume 0.00M

Average 0.97M

APGE Total Debt

Short-term and long-term borrowings combined.

Apogee Therapeutics, Inc.NASDAQ: APGE

Total Debt · Q2 FY2026 · quarter ended Jun 2026

Total debt falls 37.0% from a year ago

Total debt stood at $6.83M at the end of Q2 FY2026, down 37.0% from a year earlier and down 15.1% from the prior quarter.

Context

  • Total debt amounted to 0.5% of total assets at the end of Q2 FY2026, down 1.1 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -37.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.83M-15.1% QoQ
Last fiscal yearDec 2025
$8.85M-25.2% YoY
Year agoJun 2025
$10.85M-37.0% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.0%——
1 year-25.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
8.85M USD
Year-over-year change
-25.2%

Total Debt vs competitors

How APGE compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -37.0% is the 8th highest of 10, against a peer median of +27.6%.
  • Total debt amounts to 0.5% of total assets for APGE, versus a peer median of 10.0%.
APGE Competitors
Total Debt for APGE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AAPGAscentage Pharma Group InternationalDec 2025CN¥1.98B CNY+18.7%+3.4%49.9%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$1.2B USD+3035.4%+243.1%92.6%
CELCCelcuity Inc.Jun 2026$754.39M USD+658.8%+77.0%91.1%
ZLABZai Lab LimitedJun 2026$254.58M USD+33.0%+122.4%23.7%
LEGNLegend Biotech CorporationSep 2026$167.4M USD-59.2%+13.3%10.0%
IRONDisc Medicine, Inc.Sep 2026$61.09M USD+97.2%+11.8%8.7%
CGONCG Oncology, Inc. Common stockSep 2026$9.24M USD+27.6%-23.9%0.9%
CNTACentessa Pharmaceuticals plcMar 2026$7.37M USD-93.8%-52.3%1.1%
APGEApogee Therapeutics, Inc.Jun 2026$6.83M USD-37.0%—0.5%
XENEXenon Pharmaceuticals Inc.Sep 2026$6.01M USD-27.8%-8.7%0.5%
Peer median (excluding APGE) —+27.6%+11.8%10.0%

Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents151.89M118.32M141.79M131.55M
Short-term Investments0277.14M378.86M598.64M
Net Receivables01.21M4.7M5.96M
Inventory0000
Other Current Assets57K01.74M605K
Total Current Assets152.06M398.41M529.71M741.36M
Property, Plant & Equipment (Net)02.59M13.32M14.38M
Goodwill0000
Intangible Assets0000
Long-term Investments00210.42M0
Tax Assets0000
Other Non-current Assets0401K498K181.4M
Total Non-current Assets03M224.24M195.78M
Total Assets152.06M401.4M753.95M937.13M
Account Payables418K2.14M1.07M1.22M
Short-term Debt01.1M3.23M0
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities515K17.15M22.36M3.66M
Total Current Liabilities9.98M20.56M28.56M27.91M
Long-term Debt0005.35M
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities0000
Total Non-current Liabilities0933K8.6M5.35M
Total Liabilities9.98M21.49M37.16M33.25M
Common Stock2.25M01K1K
Retained Earnings(39.79M)(123.77M)(305.92M)(561.76M)
Accumulated OCI2.14M329K915K1.08M
Other Stockholders Equity0000
Minority Interest0000
Total Equity142.08M379.91M716.79M903.88M
Total Debt02.03M11.83M8.85M
Net Debt(151.89M)(116.28M)(129.96M)(122.7M)

Apogee Therapeutics, Inc.

NASDAQ:APGE

Intrinsic Alpha fair value

Locked

Current Price

$135.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.